Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$20.01 AUD
Change Today -0.35 / -1.72%
Volume 23.4K
SRX On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 8:09 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

sirtex medical ltd (SRX) Snapshot

Open
A$20.00
Previous Close
A$20.47
Day High
A$20.16
Day Low
A$20.00
52 Week High
03/13/15 - A$39.95
52 Week Low
03/17/15 - A$14.80
Market Cap
1.1B
Average Volume 10 Days
437.9K
EPS TTM
A$0.54
Shares Outstanding
56.5M
EX-Date
10/3/14
P/E TM
37.0x
Dividend
A$0.20
Dividend Yield
0.98%
Current Stock Chart for SIRTEX MEDICAL LTD (SRX)

Related News

No related news articles were found.

sirtex medical ltd (SRX) Related Businessweek News

No Related Businessweek News Found

sirtex medical ltd (SRX) Details

Sirtex Medical Limited, a life-sciences company, develops and distributes oncology treatments using small particle technology in the Asia Pacific, the Americas, Europe, the Middle East, and Africa. The company provides SIR-Spheres microspheres, a medical device used in interventional oncology to deliver selective internal radiation therapy to the liver. It has a collaboration agreement with Guerbet to examine ways SIR-Spheres microspheres can be combined with its imaging agent Lipiodol to address the unmet clinical needs in patients with hepatocellular carcinoma, metastatic colorectal cancer, and metastatic neuroendocrine tumours. The company is based in North Sydney, Australia.

226 Employees
Last Reported Date: 02/17/15

sirtex medical ltd (SRX) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$998.5K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$468.3K
Global Head of Operations
Total Annual Compensation: A$462.0K
Chief Executive Officer of Europe
Total Annual Compensation: A$698.1K
Chief Executive Officer of Asia Pacific Regio...
Total Annual Compensation: A$456.4K
Compensation as of Fiscal Year 2014.

sirtex medical ltd (SRX) Key Developments

Sirtex Medical Limited Reports Preliminary SIRFLOX Study Results

Sirtex Medical Limited reported the preliminary results of its SIRFLOX clinical study. Based on the preliminary analysis just completed, the primary endpoint of the SIRFLOX study was not achieved. The preliminary analysis shows that adding SIR-Spheres Y-90 resin microspheres to a current first-line systemic chemotherapy regimen for the treatment of non-resectable metastatic colorectal cancer (mCRC) does not result in a statistically significant improvement in the overall Progression-Free Survival. Overall PFS measures progression of existing tumours and/or the development of new tumours in any organ or body site. Sirtex is pleased that the preliminary analysis showed that SIR-Spheres Y-90 resin microspheres did result in a statistically significant improvement in Progression-Free Survival in the liver. This secondary study endpoint is important as liver tumours are commonly the only, or dominant, site of disease in patients with mCRC and are the major site of disease influencing survival. Up to 90% of mCRC patients die of liver failure due to the local effects of the liver tumours. SIR-Spheres Y-90 resin microspheres are specifically targeted to treat liver tumours.

Sirtex Medical Mulls Acquisitions

Sirtex Medical Limited (ASX:SRX) to pursue acquisitions. The company plans to use its $50 million in spare cash and a debt-free balance sheet to pursue acquisitions. Sirtex Medical Chief Executive Officer Gilman Wong said that the company is on the hunt for medical developments that have passed through clinical trials and are ready for commercialization. Sirtex shares increased 12.3% to $33.81.

Sirtex Medical Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Sirtex Medical Limited reported consolidated earnings results for the half year ended December 31, 2014. For the half year period, the company reported revenue from the sale of goods of AUD 80,452,000 compared to AUD 58,581,000 a year ago. Profit before income tax expense was AUD 23,925,000 compared to AUD 14,594,000 a year ago. Profit attributable to members of the parent entity was AUD 17,655,000 compared to AUD 11,170,000 a year ago. Diluted earnings per share were 30.5 cents compared to 19.5 cents a year ago. Net cash provided by operating activities was AUD 21,948,000 compared to AUD 15,892,000 a year ago. Purchase of plant and equipment was AUD 633,000 compared to AUD 3,503,000 a year ago. Purchase of intangible assets was AUD 187,000. Net tangible asset backing per ordinary security was 102.7 cents compared to 93.6 cents a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRX:AU A$20.01 AUD -0.35

SRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $16.55 USD -0.31
BTG PLC 724.00 GBp -10.00
Delcath Systems Inc $0.88 USD -0.05
View Industry Companies
 

Industry Analysis

SRX

Industry Average

Valuation SRX Industry Range
Price/Earnings 37.6x
Price/Sales 7.3x
Price/Book 9.3x
Price/Cash Flow 36.6x
TEV/Sales 7.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIRTEX MEDICAL LTD, please visit www.sirtex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.